ProCE Banner Series

Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care

Join us in person at AMCP 2023 or virtually at home for this 1.5-hour live, ACPE-certified satellite symposium on examining advances in ovarian cancer and strategies for promoting optimal and equitable care. This interactive event features expert perspectives on the evolving role of biomarkers for targeted therapy. Bring your questions for the question and answer session with the expert faculty.

  ACPE-P
Credits Available

1.5 ACPE-P

Who Should Attend

Pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with ovarian cancer and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

All Events

Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care

Past Events

March

22

2023

6:00 AM - 8:00 AM Central Time (CT)

In-personVirtual

Henry B. González Convention Center, 900 E Market St., San Antonio, Texas 78205

Faculty

ProCE Banner Faculty
Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida 

ProCE Banner Faculty
Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Topics

Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in the management of patients with ovarian cancer, including those with treatment-naive and relapsed ovarian cancer.

Target Audience
This activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with ovarian cancer and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate current and emerging data on PARP inhibitors as single agents or in combination therapies for ovarian cancer
  • Determine individualized treatment strategies for patients with newly diagnosed and recurrent or relapsed ovarian cancer that incorporate novel therapies and combination strategies
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Identify strategies to promote optimal and equitable clinical integration of approved and emerging therapies for patients with ovarian cancer to reduce associated costs, minimize healthcare disparities, and improve outcomes for patients

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-006-L01-P has been assigned to this live application-based activity (initial release date 03/22/2023). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, GSK, Immunogen, Inc., Merck Sharp & Dohme LLC, and Novocure, Inc.